This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Hepatic Impairment Study

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: January 23, 2009
Last updated: October 31, 2014
Last verified: October 2014
This study is to find out how the subject's body processes and reacts to the study drug, and to find out how long it remains in the subjects system after one dose. Subjects with varying degrees of liver function are being asked to participate in this study. Study results from subjects with normal liver function will be compared with study results from subjects with impaired liver function.

Condition Intervention Phase
Liver Disease Drug: Sorafenib (Nexavar, BAY43-9006) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Phase 1 to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib ( BAY43-9006)

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • PK measurements [ Time Frame: Day 1-6 ]

Secondary Outcome Measures:
  • Physical Exam [ Time Frame: Screening, Day 6 ]
  • Labotatory Safety, Chemistry panel, PTT, hematology Urine Analysis [ Time Frame: Screening Day 1, Day 6 ]
  • ECG [ Time Frame: Screening Day 1, Day 6 ]
  • Vital Signs [ Time Frame: Screening Day 1, Day 6 ]
  • Follow up phone call [ Time Frame: Day 14 ]

Enrollment: 45
Study Start Date: January 2009
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: Sorafenib (Nexavar, BAY43-9006)
Mildly Hepatic Impaired Subjects
Experimental: Arm 2 Drug: Sorafenib (Nexavar, BAY43-9006)
Moderately Hepatic Impaired Subjects
Experimental: Arm 3 Drug: Sorafenib (Nexavar, BAY43-9006)
Healthy Subjects


Ages Eligible for Study:   50 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy Subjects, Child Pugh A and Child Pugh B Liver Disease Patients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00829231

United States, Florida
Miami, Florida, United States, 33014
Orlando, Florida, United States, 32809
United States, Tennessee
Knoxville, Tennessee, United States, 37920
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT00829231     History of Changes
Other Study ID Numbers: 12349
Study First Received: January 23, 2009
Last Updated: October 31, 2014

Keywords provided by Bayer:
Liver disease

Additional relevant MeSH terms:
Liver Diseases
Digestive System Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs processed this record on September 20, 2017